Premium
Cimetidine in labour: absence of adverse effect on the high‐risk fetus
Author(s) -
McAULEY D. M.,
HALLIDAY H. L.,
JOHNSTON J. R.,
MOORE J.,
DUNDEE J. W.
Publication year - 1985
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1985.tb01108.x
Subject(s) - cimetidine , antacid , gestation , medicine , magnesium , pregnancy , gastrointestinal tract , adverse effect , randomized controlled trial , pediatrics , obstetrics , chemistry , biology , genetics , organic chemistry
Summary. In a prospective randomized trial, 36 women received cimetidine and 32 magnesium trisilicate mixture BP as antacid therapy every 2 h in labour. The women belonged to a high‐risk category and the infants born were <36 weeks gestation, or <2000g birthweight or otherwise in jeopardy because of severe maternal pre‐eclampsia or diabetes. Measurements of a wide range of haematological and biochemical variables revealed no differences between the two groups of babies. The frequency of complications found in the infants was similar, although infants born to the women who received magnesium trisilicate required oxygen therapy for a longer period. Cimetidine did not appear to affect the development of gastric acidity, or to increase bacterial colonization of the gastrointestinal tract in the infant.